Stage IV NSCLC Prognostic factors;Les facteurs pronostiques

Revue des Maladies Respiratoires

Volumn 25, Issue 8 C-2, 2008, Pages

  Paesmans, M ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Lung cancer; Prognostic factors; Survival

Indexed keywords

ALBUMIN; CISPLATIN; CYTOKERATIN 19 FRAGMENT; DOCETAXEL; GEMCITABINE; LACTATE DEHYDROGENASE;

ALBUMIN BLOOD LEVEL; ANEMIA; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; ELECTROCORTICOGRAPHY; HUMAN; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; MEDICAL LITERATURE; POSITRON EMISSION TOMOGRAPHY; PROBABILITY; PROGNOSIS; REVIEW; SEX DIFFERENCE; SKIN METASTASIS;

EID: 53149134672     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0761-8425(08)82014-1     Document Type: Review

References (20)

1. Brundage MD, Davies D, Mackillop WJ : Prognostic factors in non-small cell lung cancer. Chest 2002 ; 122 : 1037-57.
2. Buccheri G, Ferrigno D : Prognostic factors. Hematol Oncol Clin N Am 2004; 18 : 187-201.
3. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L on behalf of the International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions :The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thor Oncol 2007 ; 2 : 706-14.
4. Finkelstein DM, Ettinger DS, Ruckdeschel JC : Long-term survivors in metastatic non-small cell lung cancer. J Clin Oncol 1986 ; 4 : 702-9.
5. O'Connell JP, Kris MG, Gralla RJ, Groshen S, Trust A, Fiore JJ, Kelsen DP, Heelan RT, Golbey RB : Frequency and prognostic importance of pre-treatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986 ; 4 : 1604-14.
6. Albain KS, Crowley JJ, Leblanc M, Livingston RB : Survival determinants in extensive stag non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991 ; 9 : 1618-26.
7. Hespanhol V, Queiroga H, Magalhaes A, Santos AR, Coelho M, Marques A : Survival predictors in advanced non-small cell lung cancer. Lung Cancer 1995 ; 13 : 253-67.
8. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, van Cutsem O, Sergysels R, Mommen P, Klastersrky J for the European Lung Cancer Working Party. J Clin Oncol 1995 ; 13 : 1221-30.
9. Hoang T, Ronghui X, Schiller JH, Bonomi P, Johnson DH : Clinical model to predict survival in chemonaive patients with advanced non-small cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol 2005; 23 : 175-83.
10. Wakelee HA, Bernardo P, Johnson DH, Schiller JH : Changes in the natural history of non-small cell lung cancer (NSCLC) - Comparison of outcomes and characteristics in patients with advanced non-small cell lung cancer entered in eastern Cooperative Oncology Group trials before and after 1990. Cancer 2006 ; 16 : 2008-17.
11. Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Chansky K, Kelly K, Adjei AA, Jett JR : A prognostic model for advanced stage non-small cell lung cancer. Cancer 2006 ; 107 : 781-92.
12. Pallis AG, Agelaki S, Kakolyris S, Kotsakis A, Kalykaki A, Vardakis N, Papakotoulas P, Agelidou A, Geroyianni A, Agelidou M, Hatzidaki D, Mavroudis D, Georgoulias V : Chemotherapy-induced neutropenia as prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. Lung Cancer 2008; doi : 10.1016/J.lungcan.2008.03.030.
13. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, Scherpereel A, Mascaux C, Moreau M, Roelandts M, Alard S, Meert AP, Patz EF, Lafitte JJ, Sculier JP for the European Lung Cancer Working Party for the IASLC Staging Project : Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008 ; 3 : 6-12.
14. Socinski MA, Zhang C, Herndon JE, Dillman RO, Clamon G, Vokes E, Akerley W, Crawford J, Perry MC, Seagren SL, Green MR : Combined modality trials of the Cancer and Leukemia Group B in stage III non-small cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol 2004 ; 15 : 1033-41.
15. Sculier JP, Chansky K, Crowley J, van Meerbeeck J, Goldstraw P on behalf of the International Staging Committee and Participating Institutions : The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the Proposals for the 7th Edition. J Thorac Oncol 2008 ; 5 : 457-66.
16. Watine J, Friedberg B, Bouarioua N : Biological variables and stratification of patients with inoperable non-small cell bronchial cancer: recommendations for future trials. Cancer Radiother 2002 ; 6 : 209-16.
17. Pujol JL, Molinier O, Ebert W, Barlési F, Daurès JP, Buccheri G, Paesmans M, Quoix E, Moro D, Szturmowicz M, Bréchot JM : CYFRA 21-1 is a prognostic determinant in non-small cell lung cancer: results of a meta-analysis in 2,063 patients. Br J Cancer 2004 ; 90 : 2097-105.
18. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, van Cutsem O, Sergysels R, Mommen P, Klastersky J : Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party. Eur J Cancer 1997; 14 : 2326-32.
19. Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, Hill SR, Ward RL : Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer on non-small cell lung cancer: a meta-analysis. Lancet Oncol 2006 ; 7 : 741-6.
20. Non-small cell Lung Cancer Collaborative Group : Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995 ; 311 : 899-909.